Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0022 Monotherapy and in Combination With Cetuximab in KRASG12D Mutated Tumours
NCT06599502Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Oct 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of AZD0022 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and 1 more (7 arms), sponsored by AstraZeneca. Primary endpoints: Dose-Limiting Toxicity, Adverse Events and 2 more. Started Oct 2024; status: terminated.
02
Drugs
AZD0022
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06599502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599502.